Design, efficient synthesis, and anti-HIV activity of 4'-C-cyano- and 4'-C-ethynyl-2'-deoxy purine nucleosides. 2004

Satoru Kohgo, and Kohei Yamada, and Kenji Kitano, and Yuko Iwai, and Shinji Sakata, and Noriyuki Ashida, and Hiroyuki Hayakawa, and Daisuke Nameki, and Eiichi Kodama, and Masao Matsuoka, and Hiroaki Mitsuya, and Hiroshi Ohrui
Biochemicals Division, Yamasa Corporation, Chiba, Japan.

Some 4'-C-ethynyl-2'-deoxy purine nucleosides showed the most potent anti-HIV activity among the series of 4'-C-substituted 2'-deoxynucleosides whose 4'-C-substituents were methyl, ethyl, ethynyl and so on. Our hypothesis is that the smaller the substituent at the C-4' position they have, the more acceptable biological activity they show. Thus, 4'-C-cyano-2'-deoxy purine nucleosides, whose substituent is smaller than the ethynyl group, will have more potent antiviral activity. To prove our hypothesis, we planned to develop an efficient synthesis of 4'-C-cyano-2'-deoxy purine nucleosides (4'-CNdNs) and 4'-C-ethynyl-2'-deoxy purine nucleosides (4'-EdNs). Consequently, we succeeded in developing an efficient synthesis of six 2'-deoxy purine nucleosides bearing either a cyano or an ethynyl group at the C-4' position of the sugar moiety from 2'-deoxyadenosine and 2,6-diaminopurine 2'-deoxyriboside. Unfortunately, 4'-C-cyano derivatives showed lower activity against HIV-1, and two 4'-C-ethynyl derivatives suggested high toxicity in vivo.

UI MeSH Term Description Entries
D011684 Purine Nucleosides Purines with a RIBOSE attached that can be phosphorylated to PURINE NUCLEOTIDES. Purine Nucleoside,Nucleoside, Purine,Nucleosides, Purine
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Satoru Kohgo, and Kohei Yamada, and Kenji Kitano, and Yuko Iwai, and Shinji Sakata, and Noriyuki Ashida, and Hiroyuki Hayakawa, and Daisuke Nameki, and Eiichi Kodama, and Masao Matsuoka, and Hiroaki Mitsuya, and Hiroshi Ohrui
January 2009, Nucleic acids symposium series (2004),
Satoru Kohgo, and Kohei Yamada, and Kenji Kitano, and Yuko Iwai, and Shinji Sakata, and Noriyuki Ashida, and Hiroyuki Hayakawa, and Daisuke Nameki, and Eiichi Kodama, and Masao Matsuoka, and Hiroaki Mitsuya, and Hiroshi Ohrui
January 2000, Nucleic acids symposium series,
Satoru Kohgo, and Kohei Yamada, and Kenji Kitano, and Yuko Iwai, and Shinji Sakata, and Noriyuki Ashida, and Hiroyuki Hayakawa, and Daisuke Nameki, and Eiichi Kodama, and Masao Matsuoka, and Hiroaki Mitsuya, and Hiroshi Ohrui
July 2010, Bioorganic & medicinal chemistry letters,
Satoru Kohgo, and Kohei Yamada, and Kenji Kitano, and Yuko Iwai, and Shinji Sakata, and Noriyuki Ashida, and Hiroyuki Hayakawa, and Daisuke Nameki, and Eiichi Kodama, and Masao Matsuoka, and Hiroaki Mitsuya, and Hiroshi Ohrui
January 1999, Nucleosides & nucleotides,
Satoru Kohgo, and Kohei Yamada, and Kenji Kitano, and Yuko Iwai, and Shinji Sakata, and Noriyuki Ashida, and Hiroyuki Hayakawa, and Daisuke Nameki, and Eiichi Kodama, and Masao Matsuoka, and Hiroaki Mitsuya, and Hiroshi Ohrui
January 1996, Journal of medicinal chemistry,
Satoru Kohgo, and Kohei Yamada, and Kenji Kitano, and Yuko Iwai, and Shinji Sakata, and Noriyuki Ashida, and Hiroyuki Hayakawa, and Daisuke Nameki, and Eiichi Kodama, and Masao Matsuoka, and Hiroaki Mitsuya, and Hiroshi Ohrui
October 2004, Journal of medicinal chemistry,
Satoru Kohgo, and Kohei Yamada, and Kenji Kitano, and Yuko Iwai, and Shinji Sakata, and Noriyuki Ashida, and Hiroyuki Hayakawa, and Daisuke Nameki, and Eiichi Kodama, and Masao Matsuoka, and Hiroaki Mitsuya, and Hiroshi Ohrui
February 1996, Journal of medicinal chemistry,
Satoru Kohgo, and Kohei Yamada, and Kenji Kitano, and Yuko Iwai, and Shinji Sakata, and Noriyuki Ashida, and Hiroyuki Hayakawa, and Daisuke Nameki, and Eiichi Kodama, and Masao Matsuoka, and Hiroaki Mitsuya, and Hiroshi Ohrui
November 2000, Journal of medicinal chemistry,
Satoru Kohgo, and Kohei Yamada, and Kenji Kitano, and Yuko Iwai, and Shinji Sakata, and Noriyuki Ashida, and Hiroyuki Hayakawa, and Daisuke Nameki, and Eiichi Kodama, and Masao Matsuoka, and Hiroaki Mitsuya, and Hiroshi Ohrui
July 2000, Bioorganic & medicinal chemistry,
Satoru Kohgo, and Kohei Yamada, and Kenji Kitano, and Yuko Iwai, and Shinji Sakata, and Noriyuki Ashida, and Hiroyuki Hayakawa, and Daisuke Nameki, and Eiichi Kodama, and Masao Matsuoka, and Hiroaki Mitsuya, and Hiroshi Ohrui
January 2005, Nucleosides, nucleotides & nucleic acids,
Copied contents to your clipboard!